Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration.

Survey of ophthalmology - 1 Jan 2000

Fauser Sascha, Lambrou George N

Abstract excerpt

Anti-vascular endothelial growth factor (anti-VEGF) therapies for neovascular age-related macular degeneration (nAMD) have proven efficacy at a study-population level, although individual patient responses vary, with most of the patients responding well to anti-VEGF therapies, while a few respond poorly. The pathogenesis of AMD is known to have a genetic component, but it is unclear if any particular genotype can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Genetic Markers

Share to Macular Degeneration

Share to Polymorphism, Single Nucleotide

Share to Proteins

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 25596882
DOI: 10.1016/j.survophthal.2014.11.002

Genes

CFH
VEGFA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration.PMID 25596882Read ↗

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degenerationSemantic proximity Read ↗

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

Genetic associations of anti-vascular endothelial growth factor therapy response in age-related macular degeneration: a systematic review and meta-analysis.Semantic proximity Read ↗

Genetic markers of the effectiveness of anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.Semantic proximity Read ↗

Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study.Semantic proximity Read ↗

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.Semantic proximity Read ↗

Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration.Semantic proximity Read ↗

Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration.Semantic proximity Read ↗

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.